Login to Your Account

Antisoma's Stock Falls On Phase III Miss With R1549

By Nuala Moran

Wednesday, April 28, 2004
LONDON - Antisoma plc's share price was halved Monday after the company announced its lead product, R1549, failed in a Phase III ovarian cancer trial -survival of R1549-treated patients was no better than patients in the comparative arm. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription